# A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma

> **NCT02508467** · PHASE1 · COMPLETED · sponsor: **Blueprint Medicines Corporation** · enrollment: 146 (actual)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** Fisogatinib (BLU-554)

## Key facts

- **NCT ID:** NCT02508467
- **Lead sponsor:** Blueprint Medicines Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-31
- **Primary completion:** 2021-06-30
- **Final completion:** 2024-02-28
- **Target enrollment:** 146 (ACTUAL)
- **Last updated:** 2024-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02508467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02508467, "A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02508467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*